Skip to Main Content
Beta test
our new site.
(
NLM Technical Bulletin
)
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
No Study Results Posted
Related Studies
A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886)
This study is ongoing, but not recruiting participants.
Study NCT00600496 Information provided by AstraZeneca
First Received on January 15, 2008. Last Updated on March 21, 2013
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Breast Cancer
Breast Neoplasms
Colon Cancer
Colonic Cancer
Colon Neoplasms
Lung Cancer
Melanoma
Kidney Cancer
Additional conditions recognized in this trial
Carcinoma, Renal Cell
Colonic Neoplasms
Kidney Neoplasms
Lung Neoplasms
Neoplasms
More general conditions related to this trial
Adenocarcinoma
Breast Diseases
Carcinoma
Colonic Diseases
Colorectal Neoplasms
Digestive System Diseases
Digestive System Neoplasms
Gastrointestinal Diseases
Gastrointestinal Neoplasms
Intestinal Diseases
Intestinal Neoplasms
Kidney Diseases
Lung Diseases
Neoplasms by Histologic Type
Neoplasms by Site
Neoplasms, Germ Cell and Embryonal
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue
Neuroectodermal Tumors
Neuroendocrine Tumors
Nevi and Melanomas
Respiratory Tract Diseases
Respiratory Tract Neoplasms
Skin Diseases
Thoracic Neoplasms
Urogenital Neoplasms
Urologic Diseases
Urologic Neoplasms
Interventions listed in this trial
AZD6244
Dacarbazine
Erlotinib
Docetaxel
Temsirolimus
Additional drug interventions recognized in this trial
Everolimus
Sirolimus
More general drug interventions related to this trial
Alkylating Agents
Anti-Bacterial Agents
Anti-Infective Agents
Antibiotics, Antineoplastic
Antifungal Agents
Antineoplastic Agents
Antineoplastic Agents, Alkylating
Enzyme Inhibitors
Immunologic Factors
Immunosuppressive Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Protein Kinase Inhibitors
Therapeutic Uses
Sponsors listed in this trial
AstraZeneca
Back to top of Main Content
